Amarin Corp Plc (AMRN)

[sts66]

I doubt a mountain of complaints would mean anything to legal authorities - V is currently not approved for R-IT indication, insurers have no duty to cover it for off label use. Another thing - this "they'll save more money by reducing CVEs" - that's only true for integrated insurers like Kaiser, one stop shops for medical care and drug coverage - it does not apply to PBMs or individual drug plans - the cost of treating an MI does not fall on the drug plan insurer, so they don't have any incentive to cover V until AMRN gets R-IT indication on label, will just cut into profits since coverage rates for 2019 are already set in stone.